ArticleNature communications2026
Structural basis of laminin mimicry by E. coli CNF1 and its therapeutic potential for cancer immunotherapy.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The E. coli CNF1 toxin hijacks the host laminin 511 receptor, Lu/BCAM, to enter cells. Here, we present the high-resolution cryo-EM structures of full-length CNF1, the CNF1-BCAM complex, and the physiological laminin 511-BCAM complex. Structural analysis uncovers that CNF1 targets the V2 domain of BCAM, mimicking the interaction mode of laminin 511. We demonstrate that CNF1 binds BCAM with higher affinity than laminin 511, effectively displacing the physiological ligand from the cell surface. Leveraging this high-affinity interaction, we engineered a CNF1 D5-based T-cell engager (TCE). This TCE potently directs T cells to kill BCAM-overexpressing tumor cells in vitro and suppresses tumor progression in a metastatic ovarian cancer mouse model in female mice. These findings provide structural insight into how CNF1 hijacks the BCAM receptor and show how a pathogen-derived, high-affinity interaction can be harnessed to redirect T cells against BCAM-expressing tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.